Revolution Medicines Stock Today
| RVMD Stock | USD 45.42 0.76 1.65% |
Performance8 of 100
| Odds Of DistressLess than 21
|
Revolution Medicines is trading at 45.42 as of the 23rd of September 2024, a 1.65 percent decrease since the beginning of the trading day. The stock's lowest day price was 45.0. Revolution Medicines has about a 21 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Revolution Medicines are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of October 2022 and ending today, the 23rd of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of February 2020 | Category Healthcare | Classification Health Care |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. The company has 167.04 M outstanding shares of which 16.51 M shares are at this time shorted by private and institutional investors with about 17.4 trading days to cover. More on Revolution Medicines
Moving against Revolution Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Revolution Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Mark Goldsmith | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRevolution Medicines can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Revolution Medicines' financial leverage. It provides some insight into what part of Revolution Medicines' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revolution Medicines (RVMD) is traded on NASDAQ Exchange in USA. It is located in 700 Saginaw Drive, Redwood City, CA, United States, 94063 and employs 443 people. Revolution Medicines is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.59 B. Revolution Medicines conducts business under Biotechnology sector and is part of Health Care industry. The entity has 167.04 M outstanding shares of which 16.51 M shares are at this time shorted by private and institutional investors with about 17.4 trading days to cover.
Revolution Medicines currently holds about 461.43 M in cash with (350.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26.
Check Revolution Medicines Probability Of Bankruptcy
Ownership AllocationThe majority of Revolution Medicines outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Revolution Medicines to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Revolution Medicines. Please pay attention to any change in the institutional holdings of Revolution Medicines as this could imply that something significant has changed or is about to change at the company.
Check Revolution Ownership Details
Revolution Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-06-30 | 5.1 M | |
| Bellevue Group Ag | 2024-06-30 | 5 M | |
| Hhg Plc | 2024-06-30 | 4.6 M | |
| Casdin Capital, Llc | 2024-06-30 | 4.4 M | |
| Boxer Capital Llc | 2024-06-30 | 4.3 M | |
| Geode Capital Management, Llc | 2024-06-30 | 3.3 M | |
| Woodline Partners Lp | 2024-06-30 | 3.3 M | |
| Jpmorgan Chase & Co | 2024-06-30 | 3.1 M | |
| Deerfield Management Co | 2024-06-30 | 3.1 M | |
| Vanguard Group Inc | 2024-06-30 | 14.4 M | |
| Wellington Management Company Llp | 2024-06-30 | 13.7 M |
Revolution Medicines Historical Income Statement
Revolution Stock Against Markets
Revolution Medicines Corporate Management
| David Pompliano | Founding Officer | Profile | |
| Jack Anders | Chief Officer | Profile | |
| Walter Reiher | Chief Officer | Profile | |
| Path FRCP | Pres RD | Profile | |
| Margaret JD | Chief Officer | Profile | |
| Michael Fischbach | Academic Board | Profile |
Additional Information and Resources on Investing in Revolution Stock
When determining whether Revolution Medicines is a strong investment it is important to analyze Revolution Medicines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revolution Medicines' future performance. For an informed investment choice regarding Revolution Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revolution Medicines. If investors know Revolution will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revolution Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.72) | Revenue Per Share 0.005 | Quarterly Revenue Growth (0.95) | Return On Assets (0.25) | Return On Equity (0.41) |
The market value of Revolution Medicines is measured differently than its book value, which is the value of Revolution that is recorded on the company's balance sheet. Investors also form their own opinion of Revolution Medicines' value that differs from its market value or its book value, called intrinsic value, which is Revolution Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revolution Medicines' market value can be influenced by many factors that don't directly affect Revolution Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revolution Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revolution Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revolution Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.